Replimune Group (NASDAQ:REPL) Sees Large Volume Increase - Still a Buy?

Key Points

• Trading surged: About 3.13 million shares traded on the day (a ~95% rise from the prior session), with the stock last at $6.17 (up ~4.5%), trading below its 50‑ and 200‑day averages (~$7.59/$7.90) and a market cap of ~$508 million.
• Mixed analyst outlook: Six analysts rate REPL a Buy, two Hold and two Sell, producing a consensus "Hold" rating with a $10 target, though Piper Sandler and Wedbush recently raised targets to $14 and $19 respectively while Weiss maintained a "sell (D‑)" view.
• Fundamentals and insider activity: Replimune beat quarterly EPS estimates (reported -$0.77 vs. -$0.85 expected) but remains loss‑making (FY estimate -2.97 EPS), an insider sold 6,500 shares under a 10b5‑1 plan, and institutional investors own ~92.5% of the stock.

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) shares saw unusually-high trading volume on Thursday . Approximately 3,128,804 shares were traded during mid-day trading, an increase of 95% from the previous session's volume of 1,606,909 shares.The stock last traded at $6.1650 and had previously closed at $5.89.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Piper Sandler boosted their target price on shares of Replimune Group from $13.00 to $14.00 and gave the company an "overweight" rating in a research note on Thursday, February 5th. Wedbush lifted their price target on Replimune Group from $18.00 to $19.00 and gave the company an "outperform" rating in a report on Wednesday, February 4th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Replimune Group in a research report on Monday, December 29th. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Replimune Group presently has a consensus rating of "Hold" and a consensus target price of $10.00.

Replimune Group Trading Up 4.5%

The stock has a market cap of $508.22 million, a price-to-earnings ratio of -1.79 and a beta of 0.74. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60. The company's 50 day simple moving average is $7.59 and its two-hundred day simple moving average is $7.90.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Tuesday, February 3rd. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.08. Research analysts expect that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Insider Transactions at Replimune Group

In related news, insider Christopher Sarchi sold 6,500 shares of Replimune Group stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $8.01, for a total transaction of $52,065.00. Following the completion of the sale, the insider owned 151,588 shares of the company's stock, valued at approximately $1,214,219.88. This trade represents a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company's stock.

Institutional Investors Weigh In On Replimune Group

Several institutional investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Replimune Group by 17.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company's stock worth $435,000 after buying an additional 6,653 shares during the last quarter. Millennium Management LLC lifted its stake in Replimune Group by 2.8% in the first quarter. Millennium Management LLC now owns 1,223,236 shares of the company's stock valued at $11,927,000 after acquiring an additional 33,574 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Replimune Group by 20.9% in the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company's stock worth $6,729,000 after acquiring an additional 119,145 shares in the last quarter. Rhumbline Advisers grew its position in Replimune Group by 6.9% in the second quarter. Rhumbline Advisers now owns 102,005 shares of the company's stock worth $948,000 after acquiring an additional 6,616 shares in the last quarter. Finally, Sei Investments Co. increased its stake in shares of Replimune Group by 149.5% during the 2nd quarter. Sei Investments Co. now owns 30,478 shares of the company's stock worth $283,000 after purchasing an additional 18,263 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.